Together, our data demonstrate that NACT increased tumor-infiltrating CD8+ T cells, and that the addition of Pembrolizumab promoted localization of CD8+PD-1+ T cells in the vicinity of tumor cells. The gene discussed is CD8A; the disease is neoplasm.